Company Background
Health Management International Ltd (“HMI”) is a growing private healthcare provider in Malaysia. The Group’s key assets comprise of two tertiary hospitals in Malaysia, the 288-bed capacity Mahkota Medical Centre (“MMC”) in Malacca and the 218-bed capacity Regency Specialist Hospital (“RSH”) in Johor. These hospitals are supported by a network of 17 patient referral centres across the region. The Group also owns and operates the HMI Institute of Health Sciences (“HMI-IHS”) in Singapore.
Investment Merits
Initiate coverage with “Buy” rating with a DCF valuation of S$0.83. We believe that healthcare has a long-term investment potential. Asia’s favourable socio-economic landscape and supportive government policies underpins medical tourism in Malaysia. We expect earnings to grow 38.0% CAGR over the next five years, following the consolidation of NCI, expanding capacity, and realisation of operating efficiencies.
Investment Thesis
– Expansion to bring double digit growth in next five years
1) Organic growth machine, growth pipelines set to see PATMI to grow at 11.5% CAGR in the next five years.
Hospital Services contributed 97.6% to FY2016 Revenue, with the remaining 2.4% are derived from Healthcare Education and Training.
Generally, a private hospital bills has two components, i.e. the doctors’ professional fees and the hospital charges. Doctor’s professional fees include consultation and procedure fees. While hospital charges include sale of drugs and medical supplies, use of facilities (such as operating theatre, diagnostics, beds, etc.), nursing charges and laboratory tests.
Malaysia’s healthcare fees are regulated under the Private Healthcare Facilities and Services Act 1998 and Regulations 2006. The professional fees of doctors are controlled with a maximum ceiling. However, the cost of hospital care, day surgeries, screening and diagnosis services, ambulance services, and clinical laboratories, are not covered under these Acts.
As all partner doctors are independent practitioners, HMI is partially cushioned from the risk of margin compression arising from increasing doctors’ fees. On the other hand, to achieve the higher end of average bill size per patient would critically depend on the number of complex cases treated in the hospitals and the utilisation of its services and facilities.
Revenue grew at a 4-year compounded annual growth rate (“CAGR”) of 17.4% from FY2012 to FY2016; while EBIT jumped at 32.3% CAGR in the same period. The stellar performance over the past five years was due to (i) increased patient load, (ii) more specialist consultants recruited, and (iii) higher average bill size per patient. The three factors interlink with each other.
Favourable social demographics (such as burgeoning middle income, ageing populations, and increasing health awareness, etc.) and continued growth of the private insurance market will continue to drive the demand for quality healthcare services in Malaysia.
Net revenue from hospital grew at 17.7% CAGR during FY2012 to FY2016, driven by growth in: patient load in both hospitals (at 7.7% CAGR); and average bill size per patient (at 9.3% CAGR).
In FY2012, an average Inpatient Bill size is c.16x more than an average Outpatient Bill size. As its range of specialty and sub-specialty consultants expanded over the years, revenue intensity and the number of complex cases increased. Growth in average Inpatient Bill size outpaced that of Outpatient’s, with CAGRs of 20.8% and 8.0% respectively during FY2012 to FY2016. As in FY2016, an average Inpatient Bill size is c.38x more than an average Outpatient Bill size.
We expect the CAGR for patient load at average bill size to increase at 7.7% and 9.0%, respectively over the next five years, driven by expanding inpatient bed, medical consultants, facilities and services.
According to Malaysia Healthcare Travel Council* (MHTC), the number of healthcare travellers in Malaysia registered a 7.3% CAGR over 2011 to 2015. In 2015, it attracted over 850,000 medical tourists in 2015 and HMI had about 10% market share of it.
In addition, medical tourism is lucrative business for HMI as foreign patients tend to seek more intensive and costly treatment compared to local patients. MHTC estimated about RM1 billion revenue from medical tourism in Malaysia in 2016 (0.08% of 2016 Malaysia GDP) and expects to grow 30% in 2017.
Strategic location and favourable macro backdrop has put HMI in a sweet spot to capture demand from foreign patients. By providing same-day surgeries, HMI helps to save time and limit travel costs for foreign patients.
Foreign patient mix in HMI was consistent across past nine quarters at 21% of total patients. HMI is one of the hospital partners with Malaysia Healthcare Travel Council as a Partner Healthcare Provider; while its network of 17 regional patient representative offices would help to promote and cater for foreign patient demand.
Various government marketing efforts as well as improving flight and land connectivity could spur medical tourism in Malaysia. Prospects for medical tourism have heighten by recent developments in Malacca, namely (i) the construction of a new off-shore trading port in Malacca (dubbed “the Melaka Gateway”); and (ii) the expansion of Malacca International Airport. The Melaka Gateway is expected to complete by 2025. Upon completion, it is expected to bring in an additional 2.5 million international tourist arrivals per year to Malaysia. (Source: Melaka Gateway official website)
HMI’s operational beds grew at 5-year CAGR of 6.9%. Its ability to maintain occupancy rate at above 60% within the same period is a testament to its ability to draw patient demand. Within the same period, its Net Revenue from Hospital grew at 18% CAGR.
Due to strong patient demand, it intends to add a new ward to each of MMC and RSH by 1H FY2018 (end-CY2017), which will add c.30 new beds to each of the hospitals. We expect HMI to be able to maintain its occupancy rate at c.70%. We also took a conservative assumption where its c.14% increase in total inpatient beds in 1H FY2018 would support a c.10% growth in Net Revenue from Hospital.
In medium term, RSH will add a Hospital Extension Block by FY2020 to cope with the overstretched bed capacity. The new Hospital Extension Block was initially planned for Medical Block construction (which consists mainly of clinic suites). It was then re-designed to fit in more inpatient beds, clinical service areas, operating theatre capacity, as well as clinic suites. We expect a full impact kick-in by FY2021.
We expect its combined effort to grow its key disciplines, recruit new consultants, opening more Centres of Excellence (“COEs”), launching new services, and expand its marketing network both locally and overseas, to translate to 11.5% of top line growth per year over the next five years.
Please sign in to download the full report in PDF.
Important Information
This report is prepared and/or distributed by Phillip Securities Research Pte Ltd ("Phillip Securities Research"), which is a holder of a financial adviser’s licence under the Financial Advisers Act, Chapter 110 in Singapore.
By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.
The information and any analysis, forecasts, projections, expectations and opinions (collectively, the “Research”) contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.
Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.
This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient’s own independent verification and exercise of judgment. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.
Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.
Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.
Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.
To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.
The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.
This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.
This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.
IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSE
Where the report contains research analyses or reports from a foreign research house, please note:
Lin Sin has been an investment analyst in Phillip Securities Research since June 2014, where she started as an economist, focusing on China and ASEAN macroeconomics. Currently, she covers primarily the Consumers and Healthcare sectors in Singapore equities market.
She graduated with a Bachelor of Science in Mathematics and Economics from NTU.